NCT00949130

Comparative Study of NXL103 Versus Linezolid in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

A Multicenter,Investigator-blinded,Randomized, Comparative Study to Evaluate the Efficacy and Safety of Oral NXL103 Versus Oral Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 180 (actual)
• Sponsor: Novexel Inc · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to evaluate the efficacy and safety of oral NXL103 vs. established treatment of acute bacterial infection in adults.

Conditions

• Acute Bacterial Skin and Skin Structure Infections

Interventions

Type	Name	Description
DRUG	NXL103	BID for 7-14 days
DRUG	Linezolid	BID for 7-14 days

Timeline

• Start date: 2009-11-01
• Primary completion: 2010-03-01
• Completion: 2010-03-01
• First posted: 2009-07-30
• Last updated: 2010-03-18

Locations

15 sites across 2 countries: United States, Guatemala